Recent Finacing
Recent Raise
Remedy Pharmaceuticals is a clinical-stage company developing IV-formulated high-affinity Sur1–Trpm4 (NCCa-ATP) inhibitor RP-1127/CIRARA for acute CNS injuries, conducting the multi-center GAMES-RP Phase 2 severe ischemic stroke trial.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors